Diligence memo · auto-generated · as of July 2, 2026
Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Actuate Therapeutics, Inc. operates in Pharmaceuticals, based in FORT WORTH.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Actuate Therapeutics, Inc. has raised $127M in disclosed capital across 11 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $50M on 2025-04-10.
Most recent recorded round closed around 2025-06-27.
Valuation (modeled)modeled
Provath models Actuate Therapeutics, Inc. at approximately $29M (range $15M–$38M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.19× the median modeled value of Series C Pharmaceuticals companies in 2025–2027 (26 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 12 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 10.7× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 93% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 33% of those peers.
Closest niche peers: BlossomHill Therapeutics, Inc., Rivus Pharmaceuticals, Inc., Sparrow Pharmaceuticals, Inc., Arthrosi Therapeutics, Inc., Altesa BioSciences, Inc..
Peoplefiled
21 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.